Non-small cell lung cancer (NSCLC), one of the deadliest types of cancers worldwide, has
been the target of immunotherapy due to its high immune antigenicity. With the addition of …

Introduction The ASTRUM-005 trial (NCT04063163) revealed that combination serplulimab
plus chemotherapy (etoposide and carboplatin EC) treatment was associated with survival …

Background Immunotherapies can substantially improve treatment efficacy, despite their
high cost. A comprehensive overview of the cost-effectiveness analysis (CEA) of immune …

Objective: Domestic PD-1inhibitor tislelizumab has emerged as a promising treatment for
Chinese patients with driver-negative advanced or metastatic non-small cell lung cancer …

Background and objective Tislelizumab is a programmed cell death protein-1 (PD-1)
inhibitor. Tislelizumab plus chemotherapy as first-line option for advanced non-squamous …

Objective: Sugemalimab is approved in China as a first-line treatment in combination with
chemotherapy for metastatic nonsquamous non-small cell lung cancer (NSCLC). This study …

Background Programmed cell death protein‐1/programmed cell death ligand‐1 (PD‐1/L1)
inhibitor is a promising therapeutic option that can be used as either a first‐line or second …

Aims: This study aimed to evaluate the cost-effectiveness of lenvatinib plus pembrolizumab
(LP) vs. chemotherapy for patients with previously treated mismatch repair proficient …

Background: The EMPOWER-LUNG 3 clinical trial has shown that cemiplimab plus
chemotherapy (CCT) significantly extended overall survival (OS) and progression-free …

Objectives The use of immune checkpoint inhibitors, particularly PD‐1 inhibitors, has
revolutionized the treatment of advanced tumors and shown significant improvements in …